Capivasertib, Faslodex 250 mg solution for injection., Placebo to Capivasertib, Capivasertib
D3615C00001
Phase 3 small_molecule active
Quick answer
Capivasertib, Faslodex 250 mg solution for injection., Placebo to Capivasertib, Capivasertib for Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active